在特纳综合征患者的系统性炎症指数和肝功能障碍:回顾性病例对照研究
Nadia Zaegel1, Rigleta Brahimaj1, Shyuefang Battaglia-Hsu2
1Department of Endocrinology, Diabetology and Nutrition, Centre Hospitalier Universitaire and Medical Faculty, Université de Lorraine, Nancy 54000, France.
Journal of the Endocrine Society
|June 4, 2024
概括
系统性炎症指数如ALRI,APRI和GPR可能表明特纳综合征 (TS) 患者的肝功能障碍. 这些标志物在没有肝脏问题的TS患者中相比较于没有肝脏问题的TS患者中升高,以及在TS患者与健康对照者之间升高.
科学领域:
- 内分泌学 在内分泌学.
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
背景情况:
- 在特纳综合征 (TS) 中注意到肝功能异常,但潜在的机制仍然不清楚.
- 低度炎症与代谢功能障碍相关的脂肪性肝病有关,这表明TS相关肝脏问题的潜在炎症成分.
研究的目的:
- 调查特纳综合征患者系统性炎症指数和肝脏异常之间的关联.
- 评估特定的炎症标志物,包括阿斯巴酸转胺酶与淋巴细胞比率指数 (ALRI),阿斯巴酸转胺酶与血小板比率指数 (APRI),马-氨基转移酶与血小板比率 (GPR),中性粒细胞-淋巴细胞比率 (NLR) 和血小板淋巴细胞比率.
主要方法:
- 对79名特纳综合征患者的医疗记录进行了回顾性分析.
- 匹配对分析将66名TS患者与66名健康对照进行比较,年龄和BMI匹配.
- 系统性炎症指数和肝功能测试的评估.
主要成果:
- 肝功能异常在57%的TS患者中存在.
- 与正常肝功能患者相比,在患有肝功能障碍的TS患者中观察到高ALRI,APRI,GPR和NLR.
- 与健康对照组相比,匹配对分析显示TS患者的ALRI,APRI和GPR显著更高;逻辑回归证实TS诊断与这些指数和肝功能障碍相关.
结论:
- 非侵入性炎症指数 (ALRI,APRI,GPR) 在特纳综合征中显示出肝功能障碍的指标.
- 需要进一步的前性研究来验证这些发现,并确定TS系统性炎症指数的临床和预后意义.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
Cirrhosis I: Introduction
32
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
32
Cirrhosis II: Pathophysiology
53
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
53


